Secarna Pharmaceuticals GmbH & Co. KG

  • Land: Deutschland

Nachricht vom 17.10.2018 | 13:00

Secarna Pharmaceuticals to attend BIO-Europe(R) 2018 - 24th Annual International Partnering Conference

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Conference

17.10.2018 / 13:00
The issuer is solely responsible for the content of this announcement.

Secarna Pharmaceuticals to attend BIO-Europe(R) 2018 - 24th Annual International Partnering Conference

Munich/Martinsried, Germany, October 17, 2018
- Secarna Pharmaceuticals ("Secarna"), a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, today announced that the Company will participate in the upcoming BIO-Europe(R) 2018 - 24th Annual International Partnering Conference taking place from November 5 to 7, 2018 in Copenhagen, Denmark.

"With entering into a co-development agreement with Firebrand Therapeutics, Inc., a scientifically leading research and development company focusing on cancer metastasis as well as receiving a Horizon 2020 grant for the development of a novel nanomedicine as a partner in the international INAT consortium, we have seen some significant milestones for Secarna over the past months. These further validate our approach to develop highly specific, safety-optimized and efficacious antisense therapies for challenging and previously undruggable targets," said Jonas Renz, Managing Director and Co-founder of Secarna. "We are confident that we are on the right track to write new chapters in the book of antisense oligonucleotides discovery and development and are therefore looking forward to enter into discussions with potential partners and present our achievements to a wide range of industry experts."

Jonas Renz, Secarna's Managing Director and Co-Founder, will be available for one-on-one meetings with interested parties over the course of the conference.

Parties interested in meeting with Secarna Pharmaceuticals at BIO-Europe(R) 2018 are requested to send an invitation through the event's partneringONE(R) partnering software or to contact The Company will also be available for media interviews and background discussions.


About BIO-Europe(R)

BIO-Europe is the preeminent partnering conference of the European life science industry, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities and private one-to-one meetings. The BIO-Europe 2018 partnering event is expected to draw over 4,000 industry attendees for three days of high-level networking, representing upwards of 2,000 companies from over 60 countries. To learn more about the conference, please visit


About Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna's mission is to maximize the performance and output of its proprietary LNAplus(TM) antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets.


Jonas Renz
Managing Director and Co-Founder

Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375

For media enquiries:

Anne Hennecke
MC Services AG
Tel.: +49 (0)211.52 92 52 22

17.10.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Interview im Fokus

„Im europäischen Spitzenfeld der Private-Equity-Liga“

Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.


Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

HeidelbergCement AG: Vorläufiges Ergebnis von HeidelbergCement im zweiten Quartal 2020 über Markterwartungen

14. Juli 2020, 16:38

Aktuelle Research-Studie

Original-Research: German Real Estate Capital S.A. (von GBC AG): Management Interview German Real Estate Capital S.A.

14. Juli 2020